Lipid Based Drug Delivery System: A Review

Zubair, Abdul-Hamid Abubakar; Sheshe, Sadeeq Muhammad; Bashir, Muhammad Ribado; Sade, Sani Muhammad

doi:10.9734/jalsi/2021/v24i330228

Cited by 5 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This technology also aims to solve problems associated with the solubility of poorly water-soluble medicines. In addition, evidence suggests that lipid-based formulations can alter the biodistribution of a drug's toxicity by shifting it away from sensitive organs [ 93 ].…”

Section: Current Nanotechnology Techniques Used To Target Rosmentioning

confidence: 99%

Exploring novel strategies to improve anti-tumour efficiency: The potential for targeting reactive oxygen species

Chasara,

Ajayi,

Leshilo

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Current Nanotechnology Techniques Used To Target Rosmentioning

confidence: 99%

Exploring novel strategies to improve anti-tumour efficiency: The potential for targeting reactive oxygen species

Chasara,

Ajayi,

Leshilo

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Lipid-Based Drug Delivery Systems are an important class of drugs that have attracted the interest of researchers. The flexibility of the lipidic excipients, low-risk profile, amended solubility is some of the advantages favoring a lipid-based drug delivery system as an alternative technique to efficiently deliver poorly soluble drugs 13 . SNEDDS (Self nano emulsifying drug delivery system) is an isotropic, thermodynamically stable mixture of oils, surfactants, and co-surfactants, which, coming in contact with gastrointestinal fluids, leads to the formation of a fine o/w nanoemulsion on gentle agitation.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2022

IJPSR

View full text Add to dashboard Cite

Febuxostat (FXT), used for treating gout, is poorly soluble and is susceptible to enzymatic degradation when administered as tablets. The current study aims to formulate, optimize and develop a stable Liquid selfnanoemulsifying drug delivery system (L-SNEDDS) and Solid SNEDDS to improve solubility, resulting in enhanced bioavailability and further to formulate Self-Nano emulsifying Osmotic Pump Tablets (SNEOPT) for controlled drug release. A ternary plot was constructed with Capmul MCM (oil phase), Tween 80 (surfactant), and PEG 400 (co-surfactant). Further optimization was done by D-Optimal design. Optimized L-SNEDDS (F8) was then converted to S-SNEDDS by the adsorption method. Aerosil 200 was used as an adsorbent. The L-SNEDDS and S-SNEDDS were characterized and evaluated. The particle size of the optimized batch was 97.25 nm (L-SNEDDS) and 155.2 nm (S-SNEDDS). In-vitro dissolution studies showed>75% release in pH 1.2 HCl buffer and >80% in phosphate buffer pH 7.4 in 1 hour. SEM (Scanning electron microscopy) studies indicated spherical particle morphology. SNEOPT was prepared by direct compression (with NaCl as the osmogent). In-vitro release from SNEOPT showed zero-order drug release kinetics. The developed formulation was found to be superior to pure FXT with enhanced solubility, which signifies that a lipidic system is an efficacious drug delivery system for treating gout.

show abstract